Global Treatment of Blastic-Phase CML Market Growth 2026-2032
The global Treatment of Blastic-Phase CML market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Blastic-phase chronic myeloid leukemia (CML) represents the most advanced and aggressive stage of the disease, characterized by a rapid proliferation of immature myeloid or lymphoid cells, often resembling acute leukemia.Treatment for blastic-phase CML generally involves intensive therapies, including high-dose chemotherapy, targeted therapies like second-generation tyrosine kinase inhibitors, and potential allogeneic stem cell transplantation.
United States market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Treatment of Blastic-Phase CML players cover Sanofi, Pfizer, Bristol Myers Squibb, Novartis, Takeda Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Treatment of Blastic-Phase CML Industry Forecast” looks at past sales and reviews total world Treatment of Blastic-Phase CML sales in 2025, providing a comprehensive analysis by region and market sector of projected Treatment of Blastic-Phase CML sales for 2026 through 2032. With Treatment of Blastic-Phase CML sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Treatment of Blastic-Phase CML industry.
This Insight Report provides a comprehensive analysis of the global Treatment of Blastic-Phase CML landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Blastic-Phase CML portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Treatment of Blastic-Phase CML market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Blastic-Phase CML and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Blastic-Phase CML.
This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Blastic-Phase CML market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Blastic-phase chronic myeloid leukemia (CML) represents the most advanced and aggressive stage of the disease, characterized by a rapid proliferation of immature myeloid or lymphoid cells, often resembling acute leukemia.Treatment for blastic-phase CML generally involves intensive therapies, including high-dose chemotherapy, targeted therapies like second-generation tyrosine kinase inhibitors, and potential allogeneic stem cell transplantation.
United States market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Treatment of Blastic-Phase CML is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Treatment of Blastic-Phase CML players cover Sanofi, Pfizer, Bristol Myers Squibb, Novartis, Takeda Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Treatment of Blastic-Phase CML Industry Forecast” looks at past sales and reviews total world Treatment of Blastic-Phase CML sales in 2025, providing a comprehensive analysis by region and market sector of projected Treatment of Blastic-Phase CML sales for 2026 through 2032. With Treatment of Blastic-Phase CML sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Treatment of Blastic-Phase CML industry.
This Insight Report provides a comprehensive analysis of the global Treatment of Blastic-Phase CML landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Blastic-Phase CML portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Treatment of Blastic-Phase CML market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Blastic-Phase CML and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Blastic-Phase CML.
This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Blastic-Phase CML market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Chemotherapy
- Targeted Therapy with TKIs
- Allogeneic BMT or SCT
- Others
- Hospitals
- Clinics
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- Pfizer
- Bristol Myers Squibb
- Novartis
- Takeda Pharmaceuticals
- Apotex
- Dr. Reddy's Laboratories
- Chia Tai Tianqing Pharmaceutical
- Qilu Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Lunan Pharmaceutical
- HanHui Pharmaceuticals
- Hansoh Pharmaceutical
- Beacon Pharmaceuticals
- What is the 10-year outlook for the global Treatment of Blastic-Phase CML market?
- What factors are driving Treatment of Blastic-Phase CML market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Treatment of Blastic-Phase CML market opportunities vary by end market size?
- How does Treatment of Blastic-Phase CML break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Treatment of Blastic-Phase CML Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Treatment of Blastic-Phase CML by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Treatment of Blastic-Phase CML by Country/Region, 2021, 2025 & 2032
2.2 Treatment of Blastic-Phase CML Segment by Type
2.2.1 Chemotherapy
2.2.2 Targeted Therapy with TKIs
2.2.3 Allogeneic BMT or SCT
2.2.4 Others
2.2.5 Treatment of Blastic-Phase CML Sales by Type
2.2.5.1 Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
2.2.5.2 Global Treatment of Blastic-Phase CML Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Treatment of Blastic-Phase CML Sale Price by Type (2021-2026)
2.3 Treatment of Blastic-Phase CML Segment by Application
2.3.1 Hospitals
2.3.2 Clinics
2.3.3 Others
2.3.4 Treatment of Blastic-Phase CML Sales by Application
2.3.4.1 Global Treatment of Blastic-Phase CML Sale Market Share by Application (2021-2026)
2.3.4.2 Global Treatment of Blastic-Phase CML Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Treatment of Blastic-Phase CML Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Treatment of Blastic-Phase CML Breakdown Data by Company
3.1.1 Global Treatment of Blastic-Phase CML Annual Sales by Company (2021-2026)
3.1.2 Global Treatment of Blastic-Phase CML Sales Market Share by Company (2021-2026)
3.2 Global Treatment of Blastic-Phase CML Annual Revenue by Company (2021-2026)
3.2.1 Global Treatment of Blastic-Phase CML Revenue by Company (2021-2026)
3.2.2 Global Treatment of Blastic-Phase CML Revenue Market Share by Company (2021-2026)
3.3 Global Treatment of Blastic-Phase CML Sale Price by Company
3.4 Key Manufacturers Treatment of Blastic-Phase CML Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Treatment of Blastic-Phase CML Product Location Distribution
3.4.2 Players Treatment of Blastic-Phase CML Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TREATMENT OF BLASTIC-PHASE CML BY GEOGRAPHIC REGION
4.1 World Historic Treatment of Blastic-Phase CML Market Size by Geographic Region (2021-2026)
4.1.1 Global Treatment of Blastic-Phase CML Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Treatment of Blastic-Phase CML Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Treatment of Blastic-Phase CML Market Size by Country/Region (2021-2026)
4.2.1 Global Treatment of Blastic-Phase CML Annual Sales by Country/Region (2021-2026)
4.2.2 Global Treatment of Blastic-Phase CML Annual Revenue by Country/Region (2021-2026)
4.3 Americas Treatment of Blastic-Phase CML Sales Growth
4.4 APAC Treatment of Blastic-Phase CML Sales Growth
4.5 Europe Treatment of Blastic-Phase CML Sales Growth
4.6 Middle East & Africa Treatment of Blastic-Phase CML Sales Growth
5 AMERICAS
5.1 Americas Treatment of Blastic-Phase CML Sales by Country
5.1.1 Americas Treatment of Blastic-Phase CML Sales by Country (2021-2026)
5.1.2 Americas Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
5.2 Americas Treatment of Blastic-Phase CML Sales by Type (2021-2026)
5.3 Americas Treatment of Blastic-Phase CML Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Treatment of Blastic-Phase CML Sales by Region
6.1.1 APAC Treatment of Blastic-Phase CML Sales by Region (2021-2026)
6.1.2 APAC Treatment of Blastic-Phase CML Revenue by Region (2021-2026)
6.2 APAC Treatment of Blastic-Phase CML Sales by Type (2021-2026)
6.3 APAC Treatment of Blastic-Phase CML Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Treatment of Blastic-Phase CML by Country
7.1.1 Europe Treatment of Blastic-Phase CML Sales by Country (2021-2026)
7.1.2 Europe Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
7.2 Europe Treatment of Blastic-Phase CML Sales by Type (2021-2026)
7.3 Europe Treatment of Blastic-Phase CML Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Treatment of Blastic-Phase CML by Country
8.1.1 Middle East & Africa Treatment of Blastic-Phase CML Sales by Country (2021-2026)
8.1.2 Middle East & Africa Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
8.2 Middle East & Africa Treatment of Blastic-Phase CML Sales by Type (2021-2026)
8.3 Middle East & Africa Treatment of Blastic-Phase CML Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Treatment of Blastic-Phase CML
10.3 Manufacturing Process Analysis of Treatment of Blastic-Phase CML
10.4 Industry Chain Structure of Treatment of Blastic-Phase CML
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Treatment of Blastic-Phase CML Distributors
11.3 Treatment of Blastic-Phase CML Customer
12 WORLD FORECAST REVIEW FOR TREATMENT OF BLASTIC-PHASE CML BY GEOGRAPHIC REGION
12.1 Global Treatment of Blastic-Phase CML Market Size Forecast by Region
12.1.1 Global Treatment of Blastic-Phase CML Forecast by Region (2027-2032)
12.1.2 Global Treatment of Blastic-Phase CML Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Treatment of Blastic-Phase CML Forecast by Type (2027-2032)
12.7 Global Treatment of Blastic-Phase CML Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.1.3 Sanofi Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.2.3 Pfizer Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Bristol Myers Squibb
13.3.1 Bristol Myers Squibb Company Information
13.3.2 Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.3.3 Bristol Myers Squibb Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bristol Myers Squibb Main Business Overview
13.3.5 Bristol Myers Squibb Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.4.3 Novartis Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Takeda Pharmaceuticals
13.5.1 Takeda Pharmaceuticals Company Information
13.5.2 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.5.3 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Takeda Pharmaceuticals Main Business Overview
13.5.5 Takeda Pharmaceuticals Latest Developments
13.6 Apotex
13.6.1 Apotex Company Information
13.6.2 Apotex Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.6.3 Apotex Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Apotex Main Business Overview
13.6.5 Apotex Latest Developments
13.7 Dr. Reddy's Laboratories
13.7.1 Dr. Reddy's Laboratories Company Information
13.7.2 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Main Business Overview
13.7.5 Dr. Reddy's Laboratories Latest Developments
13.8 Chia Tai Tianqing Pharmaceutical
13.8.1 Chia Tai Tianqing Pharmaceutical Company Information
13.8.2 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.8.3 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.8.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Information
13.9.2 Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.9.3 Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Qilu Pharmaceutical Main Business Overview
13.9.5 Qilu Pharmaceutical Latest Developments
13.10 CSPC Ouyi Pharmaceutical
13.10.1 CSPC Ouyi Pharmaceutical Company Information
13.10.2 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.10.3 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSPC Ouyi Pharmaceutical Main Business Overview
13.10.5 CSPC Ouyi Pharmaceutical Latest Developments
13.11 Lunan Pharmaceutical
13.11.1 Lunan Pharmaceutical Company Information
13.11.2 Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.11.3 Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Lunan Pharmaceutical Main Business Overview
13.11.5 Lunan Pharmaceutical Latest Developments
13.12 HanHui Pharmaceuticals
13.12.1 HanHui Pharmaceuticals Company Information
13.12.2 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.12.3 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 HanHui Pharmaceuticals Main Business Overview
13.12.5 HanHui Pharmaceuticals Latest Developments
13.13 Hansoh Pharmaceutical
13.13.1 Hansoh Pharmaceutical Company Information
13.13.2 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.13.3 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Hansoh Pharmaceutical Main Business Overview
13.13.5 Hansoh Pharmaceutical Latest Developments
13.14 Beacon Pharmaceuticals
13.14.1 Beacon Pharmaceuticals Company Information
13.14.2 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.14.3 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beacon Pharmaceuticals Main Business Overview
13.14.5 Beacon Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Treatment of Blastic-Phase CML Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Treatment of Blastic-Phase CML by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Treatment of Blastic-Phase CML by Country/Region, 2021, 2025 & 2032
2.2 Treatment of Blastic-Phase CML Segment by Type
2.2.1 Chemotherapy
2.2.2 Targeted Therapy with TKIs
2.2.3 Allogeneic BMT or SCT
2.2.4 Others
2.2.5 Treatment of Blastic-Phase CML Sales by Type
2.2.5.1 Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
2.2.5.2 Global Treatment of Blastic-Phase CML Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Treatment of Blastic-Phase CML Sale Price by Type (2021-2026)
2.3 Treatment of Blastic-Phase CML Segment by Application
2.3.1 Hospitals
2.3.2 Clinics
2.3.3 Others
2.3.4 Treatment of Blastic-Phase CML Sales by Application
2.3.4.1 Global Treatment of Blastic-Phase CML Sale Market Share by Application (2021-2026)
2.3.4.2 Global Treatment of Blastic-Phase CML Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Treatment of Blastic-Phase CML Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Treatment of Blastic-Phase CML Breakdown Data by Company
3.1.1 Global Treatment of Blastic-Phase CML Annual Sales by Company (2021-2026)
3.1.2 Global Treatment of Blastic-Phase CML Sales Market Share by Company (2021-2026)
3.2 Global Treatment of Blastic-Phase CML Annual Revenue by Company (2021-2026)
3.2.1 Global Treatment of Blastic-Phase CML Revenue by Company (2021-2026)
3.2.2 Global Treatment of Blastic-Phase CML Revenue Market Share by Company (2021-2026)
3.3 Global Treatment of Blastic-Phase CML Sale Price by Company
3.4 Key Manufacturers Treatment of Blastic-Phase CML Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Treatment of Blastic-Phase CML Product Location Distribution
3.4.2 Players Treatment of Blastic-Phase CML Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TREATMENT OF BLASTIC-PHASE CML BY GEOGRAPHIC REGION
4.1 World Historic Treatment of Blastic-Phase CML Market Size by Geographic Region (2021-2026)
4.1.1 Global Treatment of Blastic-Phase CML Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Treatment of Blastic-Phase CML Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Treatment of Blastic-Phase CML Market Size by Country/Region (2021-2026)
4.2.1 Global Treatment of Blastic-Phase CML Annual Sales by Country/Region (2021-2026)
4.2.2 Global Treatment of Blastic-Phase CML Annual Revenue by Country/Region (2021-2026)
4.3 Americas Treatment of Blastic-Phase CML Sales Growth
4.4 APAC Treatment of Blastic-Phase CML Sales Growth
4.5 Europe Treatment of Blastic-Phase CML Sales Growth
4.6 Middle East & Africa Treatment of Blastic-Phase CML Sales Growth
5 AMERICAS
5.1 Americas Treatment of Blastic-Phase CML Sales by Country
5.1.1 Americas Treatment of Blastic-Phase CML Sales by Country (2021-2026)
5.1.2 Americas Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
5.2 Americas Treatment of Blastic-Phase CML Sales by Type (2021-2026)
5.3 Americas Treatment of Blastic-Phase CML Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Treatment of Blastic-Phase CML Sales by Region
6.1.1 APAC Treatment of Blastic-Phase CML Sales by Region (2021-2026)
6.1.2 APAC Treatment of Blastic-Phase CML Revenue by Region (2021-2026)
6.2 APAC Treatment of Blastic-Phase CML Sales by Type (2021-2026)
6.3 APAC Treatment of Blastic-Phase CML Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Treatment of Blastic-Phase CML by Country
7.1.1 Europe Treatment of Blastic-Phase CML Sales by Country (2021-2026)
7.1.2 Europe Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
7.2 Europe Treatment of Blastic-Phase CML Sales by Type (2021-2026)
7.3 Europe Treatment of Blastic-Phase CML Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Treatment of Blastic-Phase CML by Country
8.1.1 Middle East & Africa Treatment of Blastic-Phase CML Sales by Country (2021-2026)
8.1.2 Middle East & Africa Treatment of Blastic-Phase CML Revenue by Country (2021-2026)
8.2 Middle East & Africa Treatment of Blastic-Phase CML Sales by Type (2021-2026)
8.3 Middle East & Africa Treatment of Blastic-Phase CML Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Treatment of Blastic-Phase CML
10.3 Manufacturing Process Analysis of Treatment of Blastic-Phase CML
10.4 Industry Chain Structure of Treatment of Blastic-Phase CML
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Treatment of Blastic-Phase CML Distributors
11.3 Treatment of Blastic-Phase CML Customer
12 WORLD FORECAST REVIEW FOR TREATMENT OF BLASTIC-PHASE CML BY GEOGRAPHIC REGION
12.1 Global Treatment of Blastic-Phase CML Market Size Forecast by Region
12.1.1 Global Treatment of Blastic-Phase CML Forecast by Region (2027-2032)
12.1.2 Global Treatment of Blastic-Phase CML Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Treatment of Blastic-Phase CML Forecast by Type (2027-2032)
12.7 Global Treatment of Blastic-Phase CML Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.1.3 Sanofi Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.2.3 Pfizer Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Bristol Myers Squibb
13.3.1 Bristol Myers Squibb Company Information
13.3.2 Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.3.3 Bristol Myers Squibb Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bristol Myers Squibb Main Business Overview
13.3.5 Bristol Myers Squibb Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.4.3 Novartis Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Takeda Pharmaceuticals
13.5.1 Takeda Pharmaceuticals Company Information
13.5.2 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.5.3 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Takeda Pharmaceuticals Main Business Overview
13.5.5 Takeda Pharmaceuticals Latest Developments
13.6 Apotex
13.6.1 Apotex Company Information
13.6.2 Apotex Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.6.3 Apotex Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Apotex Main Business Overview
13.6.5 Apotex Latest Developments
13.7 Dr. Reddy's Laboratories
13.7.1 Dr. Reddy's Laboratories Company Information
13.7.2 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Main Business Overview
13.7.5 Dr. Reddy's Laboratories Latest Developments
13.8 Chia Tai Tianqing Pharmaceutical
13.8.1 Chia Tai Tianqing Pharmaceutical Company Information
13.8.2 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.8.3 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.8.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Information
13.9.2 Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.9.3 Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Qilu Pharmaceutical Main Business Overview
13.9.5 Qilu Pharmaceutical Latest Developments
13.10 CSPC Ouyi Pharmaceutical
13.10.1 CSPC Ouyi Pharmaceutical Company Information
13.10.2 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.10.3 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSPC Ouyi Pharmaceutical Main Business Overview
13.10.5 CSPC Ouyi Pharmaceutical Latest Developments
13.11 Lunan Pharmaceutical
13.11.1 Lunan Pharmaceutical Company Information
13.11.2 Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.11.3 Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Lunan Pharmaceutical Main Business Overview
13.11.5 Lunan Pharmaceutical Latest Developments
13.12 HanHui Pharmaceuticals
13.12.1 HanHui Pharmaceuticals Company Information
13.12.2 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.12.3 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 HanHui Pharmaceuticals Main Business Overview
13.12.5 HanHui Pharmaceuticals Latest Developments
13.13 Hansoh Pharmaceutical
13.13.1 Hansoh Pharmaceutical Company Information
13.13.2 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.13.3 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Hansoh Pharmaceutical Main Business Overview
13.13.5 Hansoh Pharmaceutical Latest Developments
13.14 Beacon Pharmaceuticals
13.14.1 Beacon Pharmaceuticals Company Information
13.14.2 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
13.14.3 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beacon Pharmaceuticals Main Business Overview
13.14.5 Beacon Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Treatment of Blastic-Phase CML Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Treatment of Blastic-Phase CML Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Targeted Therapy with TKIs
Table 5. Major Players of Allogeneic BMT or SCT
Table 6. Major Players of Others
Table 7. Global Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 8. Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Table 9. Global Treatment of Blastic-Phase CML Revenue by Type (2021-2026) & ($ million)
Table 10. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2026)
Table 11. Global Treatment of Blastic-Phase CML Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Treatment of Blastic-Phase CML Sale by Application (2021-2026) & (K Units)
Table 13. Global Treatment of Blastic-Phase CML Sale Market Share by Application (2021-2026)
Table 14. Global Treatment of Blastic-Phase CML Revenue by Application (2021-2026) & ($ million)
Table 15. Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2026)
Table 16. Global Treatment of Blastic-Phase CML Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Treatment of Blastic-Phase CML Sales by Company (2021-2026) & (K Units)
Table 18. Global Treatment of Blastic-Phase CML Sales Market Share by Company (2021-2026)
Table 19. Global Treatment of Blastic-Phase CML Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Treatment of Blastic-Phase CML Revenue Market Share by Company (2021-2026)
Table 21. Global Treatment of Blastic-Phase CML Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Treatment of Blastic-Phase CML Producing Area Distribution and Sales Area
Table 23. Players Treatment of Blastic-Phase CML Products Offered
Table 24. Treatment of Blastic-Phase CML Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Treatment of Blastic-Phase CML Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Treatment of Blastic-Phase CML Sales Market Share Geographic Region (2021-2026)
Table 29. Global Treatment of Blastic-Phase CML Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Treatment of Blastic-Phase CML Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Treatment of Blastic-Phase CML Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2021-2026)
Table 33. Global Treatment of Blastic-Phase CML Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Treatment of Blastic-Phase CML Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 36. Americas Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2026)
Table 37. Americas Treatment of Blastic-Phase CML Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 39. Americas Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 40. APAC Treatment of Blastic-Phase CML Sales by Region (2021-2026) & (K Units)
Table 41. APAC Treatment of Blastic-Phase CML Sales Market Share by Region (2021-2026)
Table 42. APAC Treatment of Blastic-Phase CML Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 44. APAC Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 45. Europe Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 46. Europe Treatment of Blastic-Phase CML Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 48. Europe Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Treatment of Blastic-Phase CML
Table 54. Key Market Challenges & Risks of Treatment of Blastic-Phase CML
Table 55. Key Industry Trends of Treatment of Blastic-Phase CML
Table 56. Treatment of Blastic-Phase CML Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Treatment of Blastic-Phase CML Distributors List
Table 59. Treatment of Blastic-Phase CML Customer List
Table 60. Global Treatment of Blastic-Phase CML Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Treatment of Blastic-Phase CML Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Treatment of Blastic-Phase CML Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Treatment of Blastic-Phase CML Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Treatment of Blastic-Phase CML Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Treatment of Blastic-Phase CML Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Treatment of Blastic-Phase CML Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Treatment of Blastic-Phase CML Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Treatment of Blastic-Phase CML Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Treatment of Blastic-Phase CML Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Treatment of Blastic-Phase CML Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sanofi Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 75. Sanofi Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 76. Sanofi Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Sanofi Main Business
Table 78. Sanofi Latest Developments
Table 79. Pfizer Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 81. Pfizer Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Bristol Myers Squibb Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 85. Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 86. Bristol Myers Squibb Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Bristol Myers Squibb Main Business
Table 88. Bristol Myers Squibb Latest Developments
Table 89. Novartis Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 90. Novartis Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 91. Novartis Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Novartis Main Business
Table 93. Novartis Latest Developments
Table 94. Takeda Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 95. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 96. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Takeda Pharmaceuticals Main Business
Table 98. Takeda Pharmaceuticals Latest Developments
Table 99. Apotex Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 100. Apotex Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 101. Apotex Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Apotex Main Business
Table 103. Apotex Latest Developments
Table 104. Dr. Reddy's Laboratories Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 105. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 106. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Dr. Reddy's Laboratories Main Business
Table 108. Dr. Reddy's Laboratories Latest Developments
Table 109. Chia Tai Tianqing Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 110. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 111. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Chia Tai Tianqing Pharmaceutical Main Business
Table 113. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 114. Qilu Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 115. Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 116. Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Qilu Pharmaceutical Main Business
Table 118. Qilu Pharmaceutical Latest Developments
Table 119. CSPC Ouyi Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 120. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 121. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. CSPC Ouyi Pharmaceutical Main Business
Table 123. CSPC Ouyi Pharmaceutical Latest Developments
Table 124. Lunan Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 125. Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 126. Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Lunan Pharmaceutical Main Business
Table 128. Lunan Pharmaceutical Latest Developments
Table 129. HanHui Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 130. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 131. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. HanHui Pharmaceuticals Main Business
Table 133. HanHui Pharmaceuticals Latest Developments
Table 134. Hansoh Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 135. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 136. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Hansoh Pharmaceutical Main Business
Table 138. Hansoh Pharmaceutical Latest Developments
Table 139. Beacon Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 140. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 141. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Beacon Pharmaceuticals Main Business
Table 143. Beacon Pharmaceuticals Latest Developments
Table 1. Treatment of Blastic-Phase CML Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Treatment of Blastic-Phase CML Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Targeted Therapy with TKIs
Table 5. Major Players of Allogeneic BMT or SCT
Table 6. Major Players of Others
Table 7. Global Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 8. Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Table 9. Global Treatment of Blastic-Phase CML Revenue by Type (2021-2026) & ($ million)
Table 10. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2026)
Table 11. Global Treatment of Blastic-Phase CML Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Treatment of Blastic-Phase CML Sale by Application (2021-2026) & (K Units)
Table 13. Global Treatment of Blastic-Phase CML Sale Market Share by Application (2021-2026)
Table 14. Global Treatment of Blastic-Phase CML Revenue by Application (2021-2026) & ($ million)
Table 15. Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2026)
Table 16. Global Treatment of Blastic-Phase CML Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Treatment of Blastic-Phase CML Sales by Company (2021-2026) & (K Units)
Table 18. Global Treatment of Blastic-Phase CML Sales Market Share by Company (2021-2026)
Table 19. Global Treatment of Blastic-Phase CML Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Treatment of Blastic-Phase CML Revenue Market Share by Company (2021-2026)
Table 21. Global Treatment of Blastic-Phase CML Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Treatment of Blastic-Phase CML Producing Area Distribution and Sales Area
Table 23. Players Treatment of Blastic-Phase CML Products Offered
Table 24. Treatment of Blastic-Phase CML Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Treatment of Blastic-Phase CML Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Treatment of Blastic-Phase CML Sales Market Share Geographic Region (2021-2026)
Table 29. Global Treatment of Blastic-Phase CML Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Treatment of Blastic-Phase CML Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Treatment of Blastic-Phase CML Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2021-2026)
Table 33. Global Treatment of Blastic-Phase CML Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Treatment of Blastic-Phase CML Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 36. Americas Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2026)
Table 37. Americas Treatment of Blastic-Phase CML Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 39. Americas Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 40. APAC Treatment of Blastic-Phase CML Sales by Region (2021-2026) & (K Units)
Table 41. APAC Treatment of Blastic-Phase CML Sales Market Share by Region (2021-2026)
Table 42. APAC Treatment of Blastic-Phase CML Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 44. APAC Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 45. Europe Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 46. Europe Treatment of Blastic-Phase CML Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 48. Europe Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Treatment of Blastic-Phase CML
Table 54. Key Market Challenges & Risks of Treatment of Blastic-Phase CML
Table 55. Key Industry Trends of Treatment of Blastic-Phase CML
Table 56. Treatment of Blastic-Phase CML Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Treatment of Blastic-Phase CML Distributors List
Table 59. Treatment of Blastic-Phase CML Customer List
Table 60. Global Treatment of Blastic-Phase CML Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Treatment of Blastic-Phase CML Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Treatment of Blastic-Phase CML Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Treatment of Blastic-Phase CML Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Treatment of Blastic-Phase CML Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Treatment of Blastic-Phase CML Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Treatment of Blastic-Phase CML Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Treatment of Blastic-Phase CML Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Treatment of Blastic-Phase CML Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Treatment of Blastic-Phase CML Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Treatment of Blastic-Phase CML Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Treatment of Blastic-Phase CML Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sanofi Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 75. Sanofi Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 76. Sanofi Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Sanofi Main Business
Table 78. Sanofi Latest Developments
Table 79. Pfizer Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 81. Pfizer Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Bristol Myers Squibb Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 85. Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 86. Bristol Myers Squibb Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Bristol Myers Squibb Main Business
Table 88. Bristol Myers Squibb Latest Developments
Table 89. Novartis Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 90. Novartis Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 91. Novartis Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Novartis Main Business
Table 93. Novartis Latest Developments
Table 94. Takeda Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 95. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 96. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Takeda Pharmaceuticals Main Business
Table 98. Takeda Pharmaceuticals Latest Developments
Table 99. Apotex Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 100. Apotex Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 101. Apotex Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Apotex Main Business
Table 103. Apotex Latest Developments
Table 104. Dr. Reddy's Laboratories Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 105. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 106. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Dr. Reddy's Laboratories Main Business
Table 108. Dr. Reddy's Laboratories Latest Developments
Table 109. Chia Tai Tianqing Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 110. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 111. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Chia Tai Tianqing Pharmaceutical Main Business
Table 113. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 114. Qilu Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 115. Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 116. Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Qilu Pharmaceutical Main Business
Table 118. Qilu Pharmaceutical Latest Developments
Table 119. CSPC Ouyi Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 120. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 121. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. CSPC Ouyi Pharmaceutical Main Business
Table 123. CSPC Ouyi Pharmaceutical Latest Developments
Table 124. Lunan Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 125. Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 126. Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Lunan Pharmaceutical Main Business
Table 128. Lunan Pharmaceutical Latest Developments
Table 129. HanHui Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 130. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 131. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. HanHui Pharmaceuticals Main Business
Table 133. HanHui Pharmaceuticals Latest Developments
Table 134. Hansoh Pharmaceutical Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 135. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 136. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Hansoh Pharmaceutical Main Business
Table 138. Hansoh Pharmaceutical Latest Developments
Table 139. Beacon Pharmaceuticals Basic Information, Treatment of Blastic-Phase CML Manufacturing Base, Sales Area and Its Competitors
Table 140. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolios and Specifications
Table 141. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Beacon Pharmaceuticals Main Business
Table 143. Beacon Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Treatment of Blastic-Phase CML
Figure 2. Treatment of Blastic-Phase CML Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Treatment of Blastic-Phase CML Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Treatment of Blastic-Phase CML Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Treatment of Blastic-Phase CML Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2025)
Figure 10. Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Chemotherapy
Figure 12. Product Picture of Targeted Therapy with TKIs
Figure 13. Product Picture of Allogeneic BMT or SCT
Figure 14. Product Picture of Others
Figure 15. Global Treatment of Blastic-Phase CML Sales Market Share by Type in 2026
Figure 16. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2026)
Figure 17. Treatment of Blastic-Phase CML Consumed in Hospitals
Figure 18. Global Treatment of Blastic-Phase CML Market: Hospitals (2021-2026) & (K Units)
Figure 19. Treatment of Blastic-Phase CML Consumed in Clinics
Figure 20. Global Treatment of Blastic-Phase CML Market: Clinics (2021-2026) & (K Units)
Figure 21. Treatment of Blastic-Phase CML Consumed in Others
Figure 22. Global Treatment of Blastic-Phase CML Market: Others (2021-2026) & (K Units)
Figure 23. Global Treatment of Blastic-Phase CML Sale Market Share by Application (2025)
Figure 24. Global Treatment of Blastic-Phase CML Revenue Market Share by Application in 2026
Figure 25. Treatment of Blastic-Phase CML Sales by Company in 2026 (K Units)
Figure 26. Global Treatment of Blastic-Phase CML Sales Market Share by Company in 2026
Figure 27. Treatment of Blastic-Phase CML Revenue by Company in 2026 ($ millions)
Figure 28. Global Treatment of Blastic-Phase CML Revenue Market Share by Company in 2026
Figure 29. Global Treatment of Blastic-Phase CML Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Treatment of Blastic-Phase CML Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 32. Americas Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 33. APAC Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 34. APAC Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 35. Europe Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 36. Europe Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 39. Americas Treatment of Blastic-Phase CML Sales Market Share by Country in 2026
Figure 40. Americas Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Figure 41. Americas Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 42. Americas Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 43. United States Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Treatment of Blastic-Phase CML Sales Market Share by Region in 2026
Figure 48. APAC Treatment of Blastic-Phase CML Revenue Market Share by Region (2021-2026)
Figure 49. APAC Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 50. APAC Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 51. China Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 55. India Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Treatment of Blastic-Phase CML Sales Market Share by Country in 2026
Figure 59. Europe Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Figure 60. Europe Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 61. Europe Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 62. Germany Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 63. France Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 70. Egypt Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Treatment of Blastic-Phase CML in 2026
Figure 76. Manufacturing Process Analysis of Treatment of Blastic-Phase CML
Figure 77. Industry Chain Structure of Treatment of Blastic-Phase CML
Figure 78. Channels of Distribution
Figure 79. Global Treatment of Blastic-Phase CML Sales Market Forecast by Region (2027-2032)
Figure 80. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Treatment of Blastic-Phase CML Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Treatment of Blastic-Phase CML Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Treatment of Blastic-Phase CML
Figure 2. Treatment of Blastic-Phase CML Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Treatment of Blastic-Phase CML Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Treatment of Blastic-Phase CML Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Treatment of Blastic-Phase CML Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2025)
Figure 10. Treatment of Blastic-Phase CML Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Chemotherapy
Figure 12. Product Picture of Targeted Therapy with TKIs
Figure 13. Product Picture of Allogeneic BMT or SCT
Figure 14. Product Picture of Others
Figure 15. Global Treatment of Blastic-Phase CML Sales Market Share by Type in 2026
Figure 16. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2026)
Figure 17. Treatment of Blastic-Phase CML Consumed in Hospitals
Figure 18. Global Treatment of Blastic-Phase CML Market: Hospitals (2021-2026) & (K Units)
Figure 19. Treatment of Blastic-Phase CML Consumed in Clinics
Figure 20. Global Treatment of Blastic-Phase CML Market: Clinics (2021-2026) & (K Units)
Figure 21. Treatment of Blastic-Phase CML Consumed in Others
Figure 22. Global Treatment of Blastic-Phase CML Market: Others (2021-2026) & (K Units)
Figure 23. Global Treatment of Blastic-Phase CML Sale Market Share by Application (2025)
Figure 24. Global Treatment of Blastic-Phase CML Revenue Market Share by Application in 2026
Figure 25. Treatment of Blastic-Phase CML Sales by Company in 2026 (K Units)
Figure 26. Global Treatment of Blastic-Phase CML Sales Market Share by Company in 2026
Figure 27. Treatment of Blastic-Phase CML Revenue by Company in 2026 ($ millions)
Figure 28. Global Treatment of Blastic-Phase CML Revenue Market Share by Company in 2026
Figure 29. Global Treatment of Blastic-Phase CML Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Treatment of Blastic-Phase CML Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 32. Americas Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 33. APAC Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 34. APAC Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 35. Europe Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 36. Europe Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Treatment of Blastic-Phase CML Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Treatment of Blastic-Phase CML Revenue 2021-2026 ($ millions)
Figure 39. Americas Treatment of Blastic-Phase CML Sales Market Share by Country in 2026
Figure 40. Americas Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Figure 41. Americas Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 42. Americas Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 43. United States Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Treatment of Blastic-Phase CML Sales Market Share by Region in 2026
Figure 48. APAC Treatment of Blastic-Phase CML Revenue Market Share by Region (2021-2026)
Figure 49. APAC Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 50. APAC Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 51. China Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 55. India Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Treatment of Blastic-Phase CML Sales Market Share by Country in 2026
Figure 59. Europe Treatment of Blastic-Phase CML Revenue Market Share by Country (2021-2026)
Figure 60. Europe Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 61. Europe Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 62. Germany Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 63. France Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026)
Figure 70. Egypt Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Treatment of Blastic-Phase CML Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Treatment of Blastic-Phase CML in 2026
Figure 76. Manufacturing Process Analysis of Treatment of Blastic-Phase CML
Figure 77. Industry Chain Structure of Treatment of Blastic-Phase CML
Figure 78. Channels of Distribution
Figure 79. Global Treatment of Blastic-Phase CML Sales Market Forecast by Region (2027-2032)
Figure 80. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Treatment of Blastic-Phase CML Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Treatment of Blastic-Phase CML Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Treatment of Blastic-Phase CML Revenue Market Share Forecast by Application (2027-2032)
